Caris CDx Partnerships
Future proof with a platform built to last.
Complete DNA and RNA gene coverage uncovers novel and complex biomarkers of today and tomorrow
Co-partnership guides optimal approach of development and validation of novel CDx programs
Regulatory and commercial reach can seamlessly bridge clinical investigations to global launch
The Optimal Approach to Develop and Validate Novel CDx Biomarkers
Maximize Insights
- Whole exome (WES), whole transcriptome (WTS)
- All variant/alteration classes
- Tissue enrichment
- Tissue agnostic CDx and tumor profiling claims support use in any solid tumor indications
De-Risk Development
- IUO materials to support analytical validation
- Validation experience (CLIA, NY state, IDE)
- Strong global clinical and regulatory experience
Accelerate Programs
- MI Trials: patient identification and enrollment
- CE mark for IVD markets
- Established routine clinical testing
Support Global Success with Established Regulatory and Commercial Reach
- MI Insights program provides biomarker based alerts for therapeutic commercial success
- Caris data to support expanding use of new therapies in real world populations
- Ability to leverage extensive salesforce and medical support for go-to market strategies
- Strong track-record of working with payers to gain access and reimbursement
Contact Us
"*" indicates required fields